GLP-1 Receptor Agonist Market Size, Share and Trends Analysis, By Drug Type (Short-Acting GLP-1 and Long-Acting GLP-1), By Route of Administration (Injectable and Oral), By Indication (Type 2 Diabetes, Obesity, Cardiovascular Diseases, and Others), By End-Use, and By Region, Forecast 2025-2032

GLP-1 Receptor Agonist Market Overview and Key Insights:

The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7% during the forecast period. Glucagon-like peptide-1 (GLP-1) agonists are a type of drug used to treat type 2 diabetes mellitus (T2DM) and obesity. This receptor interacts primarily with GLP-1, a hormone that regulates blood glucose levels, lipid metabolism, and a variety of other important biological activities.

Market Drivers:

Rising prevalence of diabetes and obesity is a key driver of revenue growth in the GLP-1 Receptor Agonist market. According to the International Diabetes Federation (IDF), in 2024, an estimated 589 million persons aged 20-79 had diabetes. In 2024, more than 9.5 million people had type 1 diabetes, including 1.9 million children and adolescents under the age of 20. Further, it is anticipated that 635 million people have impaired glucose tolerance, while 488 million have impaired fasting glucose. Diabetes-related deaths are expected to affect over 3.4 million people aged 20-79 by 2024.

GLP-1 receptor agonists have emerged as critical medicines due to their combined effects of decreasing blood glucose levels and increasing weight reduction, both of which are essential for efficient diabetes management. The growing diabetes population creates a greater target market for GLP-1 receptor agonists. Globally, drug development companies are significantly expanding manufacturing capacity these products to meet the growing demand from the market.

Drug development companies conducting rapid clinical trials are anticipated to significantly accelerate the market revenue expansion of the GLP-1 receptor market over the forecast period. For instance, in June 2024, Boehringer Ingelheim and Zealand Pharma reported notable efficacy of survodutide, their dual agonist targeting GLP-1 and glucagon receptors, in reducing liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis (MASH).

Furthermore, on February 2025, Biocon Limited, an innovation-driven global biopharmaceutical business, has announced the launch of Liraglutide, a GLP-1 peptide for diabetes and obesity, in the United Kingdom. The drug-device combination will be marketed in the United Kingdom under the names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda). The launch comes after Biocon Limited received permission for gLiraglutide from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom earlier this year, making it the first generics business to do so in a major regulated market.

Market Opportunity:

Advancements in dual and triple agonist therapies acts as an opportunity for the GLP-1 Receptor Agonist market. The development of long-acting incretin receptor agonists represents a huge step forward in the fight against the twin epidemics of type 2 diabetes mellitus and obesity. Dual and triple receptor agonists, such as tirzepatide and retatrutide, provide additional benefits by targeting several pathways involved in energy regulation, resulting in greater weight loss and better metabolic results than typical GLP-1 RAs.

On March 2025, Roche stated that it has signed an exclusive collaboration and licensing deal with Zealand Pharma.  Under the terms of this agreement, the two firms will work together to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog, as a standalone therapy and in a fixed-dose combination with Roche’s lead incretin asset CT-388.  With these advancements, there is still a significant possibility to produce innovative treatments that increase the efficacy, safety, quality, and durability of weight reduction.

Recent Trends:

Emerging trends include integration with digital health platforms, development of combination therapies, precision medicine approaches, emergence of biosimilars, and long-acting formulations.

The increased availability of biosimilars for GLP-1 receptor agonists provides cost-effective options, stimulating competition and perhaps decreasing treatment prices, hence boosting market accessibility. For instance, the most studied GLP-1 RAs for biosimilar development are liraglutide and semaglutide. Initial liraglutide biosimilar comparisons to reference liraglutide revealed similar clinical effectiveness and safety profiles. Semaglutide and beinaglutide biosimilars are also being investigated.

On January 2024, Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical business, has launched a biosimilar of the popular10,11 anti-diabetic medication Liraglutide for the first time in India. The medicine is being marketed under the brand name Lirafit after receiving approval from the medicine Controller General of India (DCGI). It has been licensed worldwide for the treatment of type 2 diabetes mellitus in adult patients, including in the United States and Europe.

Restraints & Challenges:

A shortage of numerous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has occurred, owing to a large increase in demand. The beginning of the global GLP-1 RA shortage coincided with the announcement of the 2022 ADA diabetes treatment guidelines.

The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity. Furthermore, there is a persistent shortage of liraglutide, semaglutide injections, and dulaglutide. Due to the scarcity of genuine GLP-1 receptor agonists used for type 2 diabetes and weight control, a rising number of people are accidentally taking counterfeit versions, potentially endangering their health.  Furthermore, regulatory hurdles, such as delays in permits or compliance issues, might exacerbate supply shortages.  Furthermore, unanticipated increases in demand, such as changes in treatment standards or greater sickness incidence, may strain present supply systems.

Drug Type Segment Insights and Analysis:

Based on the drug type, the GLP-1 Receptor Agonist market is segmented into Short-Acting GLP-1 and Long-Acting GLP-1.

Long-Acting GLP-1 segment contributed the largest market share in 2024. Long-acting GLP-1 receptor agonists improve glycemic control in type 2 diabetes patients while posing a low risk of hypoglycaemia due to their glucose-dependent mode of action. This class of medicine also induces weight loss and lowers blood pressure, which benefits people with type 2 diabetes by reducing their cardiovascular risk. Although long-acting GLP-1 receptor agonists commonly cause nausea, the side effect is typically short-lived, and patients generally tolerate the treatment well. Therefore, long-acting GLP-1 receptor agonists offer a viable treatment option for people with type 2 diabetes and effectively align with the ADA’s standard of care recommendations by addressing more than just blood glucose levels.

On June 2025, Camurus and Eli Lilly and Company have signed a collaboration and license agreement that gives Lilly exclusive worldwide rights to the research, development, manufacturing, and commercialization of long-acting incretin medicines for cardiometabolic health based on Camurus’ FluidCrystal technology. The arrangement includes up to four Lilly patented medicinal molecules. Camurus has the option to collect up to USD 290 million in upfront, development, and regulatory milestone payments, as well as USD 580 million in sales-based milestone payments and tiered mid-single digit royalties on worldwide net product sales.

Route of Administration Segment Insights and Analysis:

Based on the route of administration, the GLP-1 Receptor Agonist market is segmented into Injectable and Oral.

Injectable segment contributed the largest market share in 2024. GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients and potentially hold promise in addressing other medical conditions. Unlike traditional oral medications, injectable GLP-1 receptor agonists have significant advantages, including improved glycemic control, weight loss aid, and a lesser risk of hypoglycemia.

On April 2025, Meitheal Pharmaceuticals, Inc., a Chicago-based fully integrated biopharmaceutical company focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that it has received FDA approval and launched liraglutide injection (18mg/3mL), the generic equivalent of Victoza 2 in the United States. Healthcare providers administer liraglutide injection using an injector pen, and patients use it along with diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Indication Segment Insights and Analysis:

Based on the indication, the GLP-1 Receptor Agonist market is segmented into type 2 diabetes, obesity, cardiovascular diseases, liver cirrhosis, Non-alcoholic fatty liver disease (NAFLD), and others.

Type 2 diabetes segment contributed the largest market share in 2024. According to the Center of Disease Control and Prevention (CDC), more than 38 million Americans have diabetes (about one in every ten), with type 2 diabetes accounting for 90% to 95% of the total. Type 2 diabetes is most common in those aged 45 and over, but it is increasingly affecting an increasing number of adolescents, teenagers, and young adults. Furthermore, in 2021, healthcare providers in Australia diagnosed over 45,700 people with type 2 diabetes, averaging 125 new cases per day. They diagnosed males 1.4 times more often than females.

On June 2024, Teva Pharmaceuticals, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., has announced the availability of an authorized generic of Victoza (liraglutide injection 1.8mg) in the United States. This launch demonstrates Teva’s ongoing commitment to its complicated generic medication portfolio. Liraglutide injection is intended to enhance glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, as well as to lower the risk of cardiovascular events in individuals with type 2 diabetes and pre-existing cardiovascular disease.

Geographical Outlook:

GLP-1 receptor agonist market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America GLP-1 Receptor Agonist Market:

North America is registered to have largest market share in GLP-1 Receptor Agonist market in 2024. This is mainly due to the rising prevalence of diabetes and obesity, advancement in drug delivery technologies, and growing focus on preventive healthcare and personalized medicine. According to the CDC, in 2023, all U.S. states and territories had an obesity prevalence of more than 20%. Overall, the Midwest (36.0%) and South (34.7%) had the greatest obesity rates, followed by the West (29.1%) and the Northeast (28.6%). Obesity rates in 17 states and the Virgin Islands ranged from 30% to less than 35%.

Furthermore, the Canadian Community Health Survey (CCHS) reported that 30% of adult Canadians were obese in 2022. According to Statistics Canada, 13.4% of Canadians with obesity had type 2 diabetes, compared to 2.9% of those with normal weight. The rising incidence of obesity has coincided with an increase in the frequency of type 2 diabetes, putting further burden on the healthcare system.

On November 2023, the United States Food and Drug Administration (FDA) has approved Eli Lilly and Company‘s Zepbound (tirzepatide) injection, the first and only obesity medication to activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Healthcare providers recommend Zepbound for individuals who are obese or overweight and have weight-related medical conditions such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease to help them reduce and maintain weight.

Asia Pacific GLP-1 Receptor Agonist Market:

Asia Pacific is registered the fastest growth rate during the forecasted period driven by Rising prevalence of diabetes and obesity, approvals for new indications or formulations, and increasing healthcare access in emerging markets. In 2022, India had the world’s biggest number of diabetics, with 212 million, followed by China, which had 148 million. In 2022, the US had 42 million adults with diabetes. The diabetes rate among women in India has risen from 11.9% in 1990 to 23.7% in 2022, representing one of the biggest increases among other countries. The diabetes rate in men increased from 11.3% in 1990 to 21.4% in 2022.

On May 2025, Sumitomo Pharma Co., Ltd. stated that it and Novo Nordisk Pharma Ltd. have signed a co-promotion agreement in Japan for Ozempic Subcutaneous Injection 2 mg, a once-weekly subcutaneous GLP-1 receptor agonist used to treat type 2 diabetes. Through this collaboration between Novo Nordisk Pharma and Sumitomo Pharma, both of which have extensive experience and strength in promoting diabetes care products, we hope to make Ozempic available to more patients with diabetes who require this medicine.

Europe GLP-1 Receptor Agonist Market:

Europe is to register a considerable market share during the forecasted period. According to the Diabetes UK, an estimated 6.3 million people are at an increased risk of type 2 diabetes in the UK based on blood sugar levels. It is also estimated that 1.3 million people are currently living with type 2 diabetes but are yet to be diagnosed. This mean an estimated 12.1 million adults in the UK are living with diabetes or prediabetes.

On December 2024, Hikma Pharmaceuticals PLC, a worldwide pharmaceutical business, has acquired FDA approval and launched its Victoza generic counterpart, Liraglutide Injection, in the United States at a dose of 6 mg/mL. Patients use Liraglutide Injection, a Glucagon-Like Peptide-1 (GLP-1) medication, along with diet and exercise to enhance glycemic control in adults and children aged 10 and up with type 2 diabetes.

Competition Analysis:

The GLP-1 Receptor Agonist market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the GLP-1 Receptor Agonist market report are:

• Novo Nordisk
• Eli Lilly and Company
• Sanofi S.A. 
• GSK plc
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Hua Medicine
• Jiangsu Hansoh Pharmaceutical Group Co.
• Sumitomo Pharma Co., Ltd.
• Glenmark Pharmaceuticals Ltd.
• Hanmi Pharm. Co., Ltd
• Roche
• Zealand Pharma
• Biocon Limited

Strategic Developments in GLP-1 Receptor Agonist Market:

• In May 2025, Illumina, Inc. and Ovation.io, Inc., a company dedicated to creating best-in-class multiomics datasets, have announced the creation of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapy. The dataset will be made available to the pharmaceutical community to help with drug discovery and development. This cooperation is the most recent in a series of efforts to collaborate across the ecosystem and employ multimodal data to increase our understanding of biology.
• In January 2025, Novo Nordisk stated that the United States Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease progression, kidney failure (end-stage renal disease), and cardiovascular disease-related death in individuals with type 2 diabetes and chronic kidney disease (CKD). This approval, combined with its previous indications for adults with type 2 diabetes to improve glycemic control and reduce the risk of major cardiovascular events in adults with known heart disease, establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most widely indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class.
• In December 2024, Gubra A/S, a company that specializes in pre-clinical contract research and peptide-based medication discovery for metabolic and fibrotic illnesses, has announced a collaboration with Amylyx Pharmaceuticals, Inc. to develop a potential novel long-acting GLP-1 receptor antagonist. This collaboration combines Gubra’s experience in rapidly screening and finding effective peptide treatments with Amylyx’s expertise in developing innovative medications for populations with high unmet need.

Lists of Some of GLP-1 Receptor Agonist Drugs (Approved):

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of the GLP-1 Receptor Agonist Market Report:

The GLP-1 Receptor Agonist market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Drug Type Outlook (Revenue, USD Billion; 2022-2032)
  • Short-Acting GLP-1
    • Exenatide
    • Lixisenatide
  • Long-Acting GLP-1
    • Liraglutide
    • Dulaglutide
    • Semaglutide
    • Albiglutide
    • Exenatide ER
    • Others

• Route of Administration Outlook (Revenue, USD Billion; 2022-2032)
  • Injectable
    • Pens
    • Prefilled Syringes
    • Vials
  • Oral

• Indication Outlook (Revenue, USD Billion; 2022-2032)
  • Type 2 Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Liver Cirrhosis
  • Non-alcoholic fatty liver disease (NAFLD)
  • Others

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Government and Public Health Programs
  • Online Pharmacies

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the GLP-1 Receptor Agonist market report